Takeda PharmaceuticalSee all their emails

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease

A real announcement email from Takeda Pharmaceutical. Captured June 9, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease email from Takeda Pharmaceutical screenshot

Captured Announcement

Takeda press release announcing FDA acceptance of an application for ENTYVIO in pediatric patients.

Top logo, followed by a branded 'Takeda Press Release' hero section with a molecular graphic. Main content body contains the headline, date, and CTA. A feedback survey section follows, with a footer containing preference and contact links.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.